Low Pressure Surgery for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how different pressure levels during robotically-assisted radical prostatectomy (RARP) might affect surgical outcomes. One group will undergo surgery with standard pressure, while another will experience slightly lower pressure (low pressure pneumoperitoneum). The researchers aim to determine if altering the pressure impacts patient recovery or postoperative well-being. Men aged 40 or older, diagnosed with prostate cancer, and fit for surgery may qualify for this trial. As an unphased trial, it provides a unique opportunity to contribute to innovative surgical research that could enhance recovery experiences for future patients.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that low pressure pneumoperitoneum is safe for prostate cancer surgery?
Research has shown that using lower pressure on the abdomen during robotic prostate surgery is generally safe. One study found that 12 mmHg of pressure, slightly less than the usual 15 mmHg, was well-tolerated by patients. This often led to fewer complications after surgery and a quicker recovery.
Another study found that lower pressure improved patient comfort after the procedure, resulting in less pain and a faster return to normal activities. Additionally, several studies confirm that this lower pressure does not increase surgical risks. Overall, both pressure levels used in these surgeries have a strong safety record.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the impact of using lower pressure during robotic-assisted radical prostatectomy (RARP) for prostate cancer. The standard practice involves using 15mm Hg of pressure, but this trial is testing whether reducing it to 12mm Hg can offer benefits. Lower pressure might reduce complications and improve recovery by minimizing pressure on the abdomen during surgery. This approach could lead to a gentler surgical experience and potentially better outcomes for patients, sparking interest in its potential advantages.
What evidence suggests that low pressure pneumoperitoneum is effective for prostate cancer surgery?
This trial will compare different pressures used during robotic-assisted prostate surgery. Research has shown that low pressure during such surgeries can improve patient recovery. Participants in the "Reduction in Pressure" arm will receive 12mm Hg of pneumoperitoneum pressure. Studies have found that this level helps patients feel better the day after surgery and reduces the risk of bowel problems. Another study found that lower pressure improves blood flow during the operation. Overall, using low pressure appears to make the surgery safer and speeds up recovery. Meanwhile, participants in the "Standard Amount of Pressure" arm will receive the standard 15mm Hg pressure.46789
Who Is on the Research Team?
Thomas Maatman, DO
Principal Investigator
Michigan Urological Clinic
Are You a Good Fit for This Trial?
This trial is for men aged 40 or older who have been diagnosed with prostate cancer and are fit to undergo robot-assisted surgery. Participants must be able to give consent, and those who cannot understand English or are cognitively impaired cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo robotic assisted radical prostatectomy (RARP) with either 15mm Hg or 12mm Hg pneumoperitoneum pressure
Post-operative Monitoring
Participants are monitored for post-operative ileus, narcotic use, and blood loss
Follow-up
Participants are monitored for post-operative complications as measured by Clavien-Dindo Complication Score
What Are the Treatments Tested in This Trial?
Interventions
- Pressure applied during RARP
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metro Health, Michigan
Lead Sponsor